17438 Federal Register / Vol. 80, No. 62 / Wednesday, April 1, 2015 / Notices 

Secretary, 600 Pennsylvania Avenue 

NW., Suite CC–5610 (Annex D), 

Washington, DC 20580, or deliver your 

comment to the following address: 

Federal Trade Commission, Office of the 

Secretary, Constitution Center, 400 7th 

Street SW., 5th Floor, Suite 5610 

(Annex D), Washington, DC 20024. If 

possible, submit your paper comment to 

the Commission by courier or overnight 

service. 

Visit the Commission Web site at 

http://www.ftc.gov to read this Notice 

and the news release describing it. The 

FTC Act and other laws that the 

Commission administers permit the 

collection of public comments to 

consider and use in this proceeding as 

appropriate. The Commission will 

consider all timely and responsive 

public comments that it receives on or 

before April 27, 2015. You can find 

more information, including routine 

uses permitted by the Privacy Act, in 

the Commission’s privacy policy, at 

http://www.ftc.gov/ftc/privacy.htm. 

Analysis of Proposed Consent Order To 

Aid Public Comment 

The Federal Trade Commission 

(‘‘FTC’’) has accepted, subject to final 

approval, an agreement containing a 

consent order from TT of Longwood, 

Inc., also doing business as Cory 

Fairbanks Mazda. The proposed consent 

order has been placed on the public 

record for thirty (30) days for receipt of 

comments by interested persons. 

Comments received during this period 

will become part of the public record. 

After thirty (30) days, the FTC will again 

review the agreement and the comments 

received, and will decide whether it 

should withdraw from the agreement 

and take appropriate action or make 

final the agreement’s proposed order. 

The respondent is a motor vehicle 

dealer. According to the FTC’s 

complaint, the respondent has 

misrepresented: (1) Vehicle purchase 

prices; (2) that advertised prices, 

discounts, rebates, bonuses, and 

incentives are available to all 

consumers; (3) the prices for added 

features such as spoilers and sunroofs; 

(4) that vehicles are available for sale or 

lease for zero down, zero payments, or 

zero interest; (5) that vehicles are 

available for $99; and (6) that consumers 

can pay $0 at the inception of a lease to 

lease the advertised vehicle for the 

advertised monthly payment amount. 

The complaint alleges therefore that the 

representations are false and misleading 

in violation of Section 5 of the FTC Act. 

In addition, the complaint alleges the 

respondent violated the Consumer 

Leasing Act (‘‘CLA’’) and Regulation M 

for failing to disclose or to disclose 

clearly and conspicuously certain costs 

and terms when advertising vehicles for 

lease. 

The proposed order is designed to 

prevent the respondent from engaging in 

similar deceptive practices in the future. 

Part I.A of the proposed order prohibits 

the respondent from misrepresenting 

the cost of: (1) Purchasing a vehicle with 

financing, including but not necessarily 

limited to the amount or percentage of 

the down payment, the number of 

payments or period of repayment, the 

amount of any payment, and the 

repayment obligation over the full term 

of the loan, including any balloon 

payment; or (2) leasing a vehicle, 

including but not limited to the total 

amount due at lease inception, the 

down payment, amount down, 

acquisition fee, capitalized cost 

reduction, any other amount required to 

be paid at lease inception, and the 

amounts of all monthly or other 

periodic payments. Part I.B prohibits the 

respondent from misrepresenting any 

other material fact about the price, sale, 

financing, or leasing of any vehicle. 

Part II.A of the proposed order 

prohibits respondent from representing 

that a discount, rebate, bonus, incentive 

or price is available unless: (1) It is 

available to all consumers, and for all 

vehicles advertised; or (2) the 

representation clearly and 

conspicuously discloses all 

qualifications or restrictions on: (a) A 

consumer’s ability to obtain the 

discount, rebate, bonus, incentive, or 

price and (b) the vehicles available at 

the discount, rebate, bonus incentive, or 

price. Part II.B prohibits respondent 

from misrepresenting any of the 

following: (1) The existence or amount 

of any discount, rebate, bonus, 

incentive, or price; (2) the existence, 

price, value, coverage, or features of any 

product or service associated with the 

motor vehicle purchase; (3) the number 

of vehicles available at particular prices; 

or (4) any other material fact about the 

price, sale, financing, or leasing of 

motor vehicles. 

Part III of the proposed order 

addresses the CLA allegations. Part III.A 

prohibits the respondent from stating 

the amount of any payment or that any 

or no initial payment is required at lease 

inception without disclosing clearly and 

conspicuously: (1) That the transaction 

advertised is a lease; (2) the total 

amount due at lease signing or delivery; 

(3) whether or not a security deposit is 

required; (4) the number, amounts, and 

timing of scheduled payments; and (5) 

that an extra charge may be imposed at 

the end of the lease term. Part III.B 

prohibits the respondent from violating 

any provision of the CLA or Regulation 

M. 

Part IV of the proposed order requires 

the respondent to keep copies of 

relevant advertisements and materials 

substantiating claims made in the 

advertisements. Part V requires the 

respondent to provide copies of the 

order to certain of its personnel. Part VI 

requires notification to the Commission 

regarding changes in corporate structure 

that might affect compliance obligations 

under the order. Part VII requires the 

respondent to file compliance reports 

with the Commission. Finally, Part VIII 

is a provision ‘‘sunsetting’’ the order 

after twenty (20) years, with certain 

exceptions. 

The purpose of this analysis is to aid 

public comment on the proposed order. 

It is not intended to constitute an 

official interpretation of the complaint 

or proposed order, or to modify in any 

way the proposed order’s terms. 

By direction of the Commission. 

Donald S. Clark, 

Secretary. 

[FR Doc. 2015–07407 Filed 3–31–15; 8:45 am] 

BILLING CODE 6750–01–P 

GENERAL SERVICES 

ADMINISTRATION 

[Notice–MVC–2015–01, Docket No. 2015– 

0054, Sequence 1] 

National Dialogue and Pilot To Reduce 

Reporting Compliance Costs for 

Federal Contractors and Grantees 

AGENCY: General Services 

Administration (GSA) and Department 

of Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Chief Acquisition 

Officers Council, Department of Health 

and Human Services, and the General 

Services Administration (GSA) are 

conducting a national dialogue to 

discuss ideas on how to reduce the costs 

(compliance and other) associated with 

reporting compliance under Federal 

awards (contracts, subcontracts, grants, 

subgrants, and cooperative agreements). 

This dialogue is part of an effort to 

improve the economy and efficiency of 

the federal award system by identifying 

impactful steps that can be taken to 

streamline, reporting, reduce burden, 

and reduce costs. 

DATES: Interested parties may 

participate in the national dialogue 

through an online platform by reviewing 

the information and participation dates 

posted at www.cao.gov. The dialogue 

will open on May 30, 2015 and close on 

May 30, 2017. 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 80, No. 62 / Wednesday, April 1, 2015 / Notices 17439 

ADDRESSES: Interested parties may 

participate in the dialogue through the 

online platform by reviewing the 

information and participation dates 

posted at www.cao.gov. 

FOR FURTHER INFORMATION CONTACT: 

Christopher Zeleznik at dataactpmo@

hhs.gov or 202–205–3514 or Emily 

Gartland at IAEOutreach@gsa.gov or 

703–605–2532. 

SUPPLEMENTARY INFORMATION: 

This notice announces a dialogue to 

explore opportunities to streamline 

processes and reduce or eliminate 

burden in federal procurement and 

grants processes. This dialogue furthers 

the goals of the President’s Management 

Agenda, which lays the foundation for 

creating a 21st century government that 

delivers better results to the American 

people, and addresses requirements in 

the Digital Accountability and 

Transparency Act of 2014 (Public Law 

113–101) to gain a better understanding 

of the costs of compliance with Federal 

contracting and grants awards as well as 

recommendations to standardize data, 

eliminate unnecessary duplication, and 

reduce compliance costs. 

During last year’s Open Dialogue on 

Federal Procurement, published in the 

Federal Register at 79 FR 22682, on 

April 23, 2014, many commenters 

pointed to the potential reduction of 

redundant reporting and related 

processes as one way to improve the 

efficiency and effectiveness of the 

government’s acquisition practices. This 

feedback is helping to support ongoing 

efforts to modernize the IT 

infrastructure supporting Federal 

procurement data collection and 

display, which will include 

development of a single Web site for 

Federal contractors to use for federal 

contract reporting requirements. 

Management of federal contract and 

grant business arrangements requires 

multiple layers of reporting across 

multiple agencies. In some cases, lack of 

standardization results in slight (or 

significant) variations in reports that 

create additional administrative and 

burdensome requirements for awardees 

that could be readily rectified. This 

dialogue is intended to continue the 

conversation begun last year in the 

context of federal procurement and 

expand it to cover federal grants by 

identifying opportunities for reducing 

burden, discussing ideas for 

standardizing processes and forms, and 

identifying recommended actions to 

reduce costs and eliminate duplication 

for awardees. The open dialogue focuses 

on three topics (campaigns). Each 

campaign focuses on a unique aspect of 

the Federal contracting and grants 

process for which we welcome your 

insight, ideas, and feedback. 

• Campaign 1—Reporting compliance 

requirements shared by prime and subawardees of Federal procurements and 

grants. 

• Campaign 2—Procurement 

practices, processes, and reporting. 

• Campaign 3—Grants practices and 

processes. 

Note—We are looking for ideas to 

reduce your burden through data 

standards and changes to reporting 

procedures. We are interested in hearing 

about proposed changes that can be 

accomplished through executive 

(regulatory, administrative, or 

management) action, as well as 

potential legislative proposals where 

requirements are based in statute. 

To facilitate a national dialogue, an 

online platform will be launched in May 

2015 so that interested parties may 

submit ideas, comment on others, 

respond to questions posed by 

moderators, and vote to indicate which 

ideas they think are most promising and 

impactful. Information on the platform, 

and the dates for participating in the 

dialogue, will be posted at www.cao.gov. 

A separate notice will beposted to 

address additional dialogue topics on 

federal procurement for conversation 

later in the spring and summer. 

Dated: March 27, 2015. 

William Clark, 

Director, Office of Government-wide 

Acquisition Policy, Office of Acquisition 

Policy, Office of Government-wide Policy. 

[FR Doc. 2015–07441 Filed 3–31–15; 8:45 am] 

BILLING CODE 6820–EP–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2015–D–0838] 

Procedures for Meetings of the Medical 

Devices Advisory Committee; Draft 

Guidance for Industry and Food and 

Drug Administration Staff; Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

availability of the draft guidance 

entitled ‘‘Procedures for Meetings of the 

Medical Devices Advisory Committee.’’ 

The Center for Devices and Radiological 

Health (CDRH) is issuing this guidance 

to provide additional information 

regarding the processes for meetings of 

the Medical Devices Advisory 

Committee panels other than the 

Dispute Resolution Panel (DRP). This 

guidance describes the general 

circumstances in which CDRH consults 

with a panel, the process for exchange 

of information between CDRH, the 

members of the panel, industry, and the 

public, and the conduct of panel 

meetings. This guidance supplements 

existing FDA Agency-wide guidance on 

the conduct of Advisory Committee 

meetings. This draft guidance is not 

final nor is it in effect at this time. 

DATES: Although you can comment on 

any guidance at any time (see 21 CFR 

10.115(g)(5)), to ensure that the Agency 

considers your comment of this draft 

guidance before it begins work on the 

final version of the guidance, submit 

either electronic or written comments 

on the draft guidance by June 1, 2015. 

ADDRESSES: An electronic copy of the 

guidance document is available for 

download from the Internet. See the 

SUPPLEMENTARY INFORMATION section for 

information on electronic access to the 

guidance. Submit written requests for a 

single hard copy of the draft guidance 

document entitled ‘‘Procedures for 

Meetings of the Medical Devices 

Advisory Committee’’ to the Office of 

the Center Director, Guidance and 

Policy Development, Center for Devices 

and Radiological Health, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 66, Rm. 5431, Silver Spring, 

MD 20993–0002. Send one selfaddressed adhesive label to assist that 

office in processing your request. 

Submit electronic comments on the 

draft guidance to http://

www.regulations.gov. Submit written 

comments to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, Rm. 

1061, Rockville, MD 20852. Identify 

comments with the docket number 

found in brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

James Swink, Center for Devices and 

Radiological Health, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 66, Rm. 1609, Silver Spring, 

MD 20993–0002, 301–796–6313. 

SUPPLEMENTARY INFORMATION: 

I. Background 

CDRH is issuing this draft guidance to 

provide additional information 

regarding the processes for meetings of 

the Medical Devices Advisory 

Committee panels other than the DRP. 

The term ‘‘panel,’’ as used in this 

guidance, refers to the panels 

established under the Medical Devices 

Advisory Committee charter excluding 

the DRP. This guidance describes the 

mstockstill on DSK4VPTVN1PROD with NOTICES